Growth hormone substitution increases gene expression of members of the IGF family in cortical bone from women with adult onset growth hormone deficiency-relationship with bone turn-over

Bone

Volumn 33, Issue 4, 2003, Pages 638-645

  Ueland, T ^a,b   Odgren, P R ^b   Yndestad, A ^a   Godang, K ^a   Schreiner, T ^a   Marks Jr , S C ^b   Bollerslev, J ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

Gene expression; Growth hormone deficiency; Insulin like growth factors; Osteoprotegerin

Indexed keywords

BIOCHEMICAL MARKER; CALCITONIN RECEPTOR; GROWTH HORMONE; GROWTH HORMONE RECEPTOR; OSTEOPROTEGERIN; PLACEBO; SOMATOMEDIN;

ADULT; ARTICLE; BONE; BONE BIOPSY; BONE DENSITY; BONE MATRIX; BONE METABOLISM; BONE MINERAL; CELL ACTIVITY; CIRCULATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORTICAL BONE; DERIVATIZATION; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG RESPONSE; FEMALE; FOLLOW UP; GENDER; GENE EXPRESSION; GROWTH HORMONE DEFICIENCY; HORMONE SUBSTITUTION; HUMAN; HUMAN TISSUE; LIVER; MEASUREMENT; NUCLEOTIDE SEQUENCE; ONSET AGE; OSSIFICATION; OSTEOCLAST; OSTEOLYSIS; PROTEIN FAMILY; RANDOMIZED CONTROLLED TRIAL;

EID: 0141750655     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/S8756-3282(03)00240-0     Document Type: Article

References (37)

1. Andreassen T.T., Melsen F., Oxlund H. The influence of growth hormone on cancellous and cortical bone of the vertebral body in aged rats. J Bone Miner Res. 11:1996;1094-1102.
2. Bord S., Ireland D.C., Beavan S.R., Compston J.E. The effects of estrogen on osteoprotegerin, RANKL, and estrogen receptor expression in human osteoblasts. Bone. 32:2003;136-141.
3. Bravenboer N., Holzmann P., de Boer H., Roos J.C., van der Veen E.A., Lips P. The effect of growth hormone (GH) on histomorphometric indices of bone structure and bone turnover in GH-deficient men. J Clin Endocrinol Metab. 82:1997;1818-1822.
4. Bustin S.A. Absolute quantification of mRNA using real-time reverse transcription polymerase chain reaction assays. J Mol Endocrinol. 25:2000;169-193.
5. Butler A.A., Funk B., Breier B.H., LeRoith D., Roberts C.T. Jr, Gluckman P.D. Growth hormone (GH) status regulates GH receptor and GH binding protein mRNA in a tissue- and transcript-specific manner but has no effect on insulin-like growth factor-I receptor mRNA in the rat. Mol Cell Endocrinol. 116:1996;181-189.
6. Chihara K., Sugimoto T. The action of GH/IGF-I/IGFBP in osteoblasts and osteoclasts. Horm Res. 48:(Suppl 5):1997;45-49.
7. Derfalvi B., Szalai C., Mandi Y., Kiraly A., Falus A. Growth hormone receptor gene expression on human lymphocytic and monocytic cell lines. Cell Biol Int. 22:1998;849-853.
8. Devlin R.D., Du Z., Buccilli V., Jorgetti V., Canalis E. Transgenic mice overexpressing insulin-like growth factor binding protein-5 display transiently decreased osteoblastic function and osteopenia. Endocrinology. 143:2002;3955-3962.
9. Fernholm R., Bramnert M., Hagg E., Hilding A., Baylink D.J., Mohan S., Thoren M. Growth hormone replacement therapy improves body composition and increases bone metabolism in elderly patients with pituitary disease. J Clin Endocrinol Metab. 85:2000;4104-4112.
10. Fisker S., Kristensen K., Rosenfalck A.M., Pedersen S.B., Ebdrup L., Richelsen B., Hilsted J., Christiansen J.S., Jorgensen J.O. Gene expression of a truncated and the full-length growth hormone (GH) receptor in subcutaneous fat and skeletal muscle in GH-deficient adults impact of GH treatment . J Clin Endocrinol Metab. 86:2001;792-796.
11. Gevers E.F., Loveridge N., Robinson I.C. Bone marrow adipocytes a neglected target tissue for growth hormone . Endocrinology. 143:2002;4065-4073.
12. Godang K., Ueland T., Bollerslev J. Decreased bone area, bone mineral content, formative markers, and increased bone resorptive markers in endogenous Cushing's syndrome. Eur J Endocrinol. 141:1999;126-131.
13. Guicheux J., Heymann D., Rousselle A.V., Gouin F., Pilet P., Yamada S., Daculsi G. Growth hormone stimulatory effects on osteoclastic resorption are partly mediated by insulin-like growth factor I an in vitro study . Bone. 22:1998;25-31.
14. Hofbauer L.C., Heufelder A.E. Clinical review 114 hot topic. The role of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in the pathogenesis and treatment of metabolic bone diseases . J Clin Endocrinol Metab. 85:2000;2355-2363.
15. Hofbauer L.C., Khosla S., Dunstan C.R., Lacey D.L., Spelsberg T.C., Riggs B.L. Estrogen stimulates gene expression and protein production of osteoprotegerin in human osteoblastic cells. Endocrinology. 140:1999;4367-4370.
16. Kamel A., Margery V., Norstedt G., Thoren M., Lindgren A.C., Bronnegard M., Marcus C. Growth hormone (GH) treatment up-regulates GH receptor mRNA levels in adipocytes from patients with GH deficiency and Prader-Willi syndrome. Pediatr Res. 38:1995;418-421.
17. Kuliwaba J.S., Findlay D.M., Atkins G.J., Forwood M.R., Fazzalari N.L. Enhanced expression of osteocalcin mRNA in human osteoarthritic trabecular bone of the proximal femur is associated with decreased expression of interleukin-6 and interleukin-11 mRNA. J Bone Miner Res. 15:2000;332-341.
18. Lanzi R., Losa M., Villa I., Gatti E., Sirtori M., Dal Fiume C., Rubinacci A. GH replacement therapy increases plasma osteoprotegerin levels in GH-deficient adults. Eur J Endocrinol. 148:2003;185-191.
19. Lin J., Kawano H., Paparella M.M., Ho S.B. Improved RNA analysis for immediate autopsy of temporal bone soft tissues. Acta Otolaryngol. 119:1999;787-795.
20. McCarthy T.L., Casinghino S., Centrella M., Canalis E. Complex pattern of insulin-like growth factor binding protein expression in primary rat osteoblast enriched cultures regulation by prostaglandin E2, growth hormone, and the insulin-like growth factors . J Cell Physiol. 160:1994;163-175.
21. Mochizuki H., Hakeda Y., Wakatsuki N., Usui N., Akashi S., Sato T., Tanaka K., Kumegawa M. Insulin-like growth factor-I supports formation and activation of osteoclasts. Endocrinology. 131:1992;1075-1080.
22. Ohlsson C., Bengtsson B.A., Isaksson O.G., Andreassen T.T., Slootweg M.C. Growth hormone and bone. Endocr Rev. 19:1998;55-79.
23. Ono T., Kanzaki S., Seino Y., Baylink D.J., Mohan S. Growth hormone (GH) treatment of GH- deficient children increases serum levels of insulin-like growth factors (IGFs), IGF-binding protein-3 and -5, and bone alkaline phosphatase isoenzyme. J Clin Endocrinol Metab. 81:1996;2111-2116.
24. Rubin J., Ackert-Bicknell C.L., Zhu L., Fan X., Murphy T.C., Nanes M.S., Marcus R., Holloway L., Beamer W.G., Rosen C.J. IGF-I regulates osteoprotegerin (OPG) and receptor activator of nuclear factor-kappaB ligand in vitro and OPG in vivo. J Clin Endocrinol Metab. 87:2002;4273-4279.
25. Salih M.A., Orhii P.B., Chen C., Kalu D.N. Growth hormone and the expression of mRNAs for matrix proteins and oncogenes in bone. Mol Cell Endocrinol. 147:1999;149-159.
26. Schneider M.R., Wolf E., Hoeflich A., Lahm H. IGF-binding protein-5 flexible player in the IGF system and effector on its own . J Endocrinol. 172:2002;423-440.
27. Sjogren K., Liu J.L., Blad K., Skrtic S., Vidal O., Wallenius V., LeRoith D., Tornell J., Isaksson O.G., Jansson J.O., Ohlsson C. Liver-derived insulin-like growth factor I (IGF-I) is the principal source of IGF-I in blood but is not required for postnatal body growth in mice. Proc Natl Acad Sci USA. 96:1999;7088-7092.
28. Sjogren K., Sheng M., Moverare S., Liu J.L., Wallenius K., Tornell J., Isaksson O., Jansson J.O., Mohan S., Ohlsson C. Effects of liver-derived insulin-like growth factor I on bone metabolism in mice. J Bone Miner Res. 17:2002;1977-1987.
29. Thoren M., Hilding A., Brismar T., Magnusson P., Degerblad M., Larsson L., Saaf M., Baylink D.J., Mohan S. Serum levels of insulin-like growth factor binding proteins (IGFBP)-4 and -5 correlate with bone mineral density in growth hormone (GH)-deficient adults and increase with GH replacement therapy. J Bone Miner Res. 13:1998;891-899.
30. Ueland T., Bollerslev J., Flyvbjerg A., Hansen T.B., Vahl N., Mosekilde L. Effects of 12 Months of Growth Hormone (GH) Treatment on Cortical and Trabecular bone content of Insulin Like Growth Factors (IGF) and Osteoprotegerin in Adults with Acquired GH Deficiency A Double Blind, Randomized, Placebo-Controlled study . J Clin Endocrinol Metab. 87:2002;2760-2763.
31. Ueland T., Bollerslev J., Godang K., Muller F., Froland S.S., Aukrust P. Increased serum osteoprotegerin in disorders characterized by persistent immune activation or glucocorticoid excess - possible role in bone homeostasis. Eur J Endocrinol. 145:2001;685-690.
32. Ueland T., Bollerslev J., Hansen T.B., Ebbesen E.N., Mosekilde L., Brixen K., Flyvbjerg A., Djoseland O. Increased cortical bone content of insulin-like growth factors in acromegalic patients. J Clin Endocrinol Metab. 84:1999;123-127.
33. Ueland T., Brixen K., Mosekilde L., Mosekilde L., Flyvbjerg A., Bollerslev J. Age-related changes in cortical bone content of insulin-like growth factor binding protein (IGFBP)-3, IGFBP-5, osteoprotegerin, and calcium in postmenopausal osteoporosis a cross-sectional study . J Clin Endocrinol Metab. 88:2003;1014-1018.
34. Ueland T., Ebbesen E.N., Thomsen J.S., Mosekilde L., Brixen K., Flyvbjerg A., Bollerslev J. Decreased trabecular bone biomechanical competence, apparent density, IGF-II and IGFBP-5 content in acromegaly. Eur J Clin Invest. 32:2002;122-128.
35. Wolthers T., Hoffman D.M., Nugent A.G., Duncan M.W., Umpleby M., Ho K.K. Oral estrogen antagonizes the metabolic actions of growth hormone in growth hormone-deficient women. Am J Physiol Endocrinol Metab. 281:2001;E1191-1196.
36. Yakar S., Liu J.L., Stannard B., Butler A., Accili D., Sauer B., LeRoith D. Normal growth and development in the absence of hepatic insulin-like growth factor 1. Proc Natl Acad Sci USA. 96:1999;7324-7329.
37. Yakar S., Rosen C.J., Beamer W.G., Ackert-Bicknell C.L., Wu Y., Liu J.L., Ooi G.T., Setser J., Frystyk J., Boisclair Y.R., LeRoith D. Circulating levels of IGF-I directly regulate bone growth and density. J Clin Invest. 110:2002;771-781.